Sinopharm

1099.HKPhase 3

Sinopharm is a Fortune Global 500 company and China's largest pharmaceutical conglomerate, encompassing drug distribution, manufacturing, research and development, and healthcare services. The company gained global recognition for developing one of China's first approved COVID-19 vaccines (BBIBP-CorV) and has established itself as a key player in international vaccine diplomacy. With operations spanning across multiple therapeutic areas and a vast distribution network, Sinopharm serves as a critical component of China's healthcare infrastructure.

Market Cap

$3.6B

Employees

150,000+

Focus

Biotech

1099.HK · Stock Price

USD 20.86+1.12 (+5.67%)

Historical price data

AI Company Overview

Technology Platform

Integrated pharmaceutical platform combining vaccine development using inactivated virus technology, traditional Chinese medicine standardization, large-scale biologics manufacturing, and advanced pharmaceutical distribution systems.

Pipeline Snapshot

4 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
SPT-07A injection	Stroke, Acute	Phase 3
Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo	COVID-19	Phase 2
Unfractionated heparin	Primary PCI	Pre-clinical
Osmotic drugs	Stroke	Pre-clinical

Opportunities

Sinopharm has significant opportunities in expanding its international vaccine business, leveraging China's Belt and Road Initiative for market access, and capitalizing on the growing demand for affordable vaccines in emerging markets.

The company's established manufacturing capabilities and government support position it well for continued global expansion.

Risk Factors

Key risks include regulatory challenges in international markets, geopolitical tensions affecting global operations, and intense competition from established Western pharmaceutical companies.

Quality control across its vast manufacturing network and potential technology transfer restrictions also pose ongoing challenges.

Competitive Landscape

Sinopharm competes globally with major vaccine manufacturers like Pfizer, Johnson & Johnson, and Sanofi, while domestically facing competition from companies like Fosun Pharma and Jiangsu Hengrui. Its key advantages include state backing, cost-effective manufacturing, and strong presence in emerging markets, though it faces challenges in premium Western markets.

Publications

Pipeline